WO2018148445A1 - Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer - Google Patents

Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer Download PDF

Info

Publication number
WO2018148445A1
WO2018148445A1 PCT/US2018/017470 US2018017470W WO2018148445A1 WO 2018148445 A1 WO2018148445 A1 WO 2018148445A1 US 2018017470 W US2018017470 W US 2018017470W WO 2018148445 A1 WO2018148445 A1 WO 2018148445A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cancer
antigen
tumor
nkg2d
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/017470
Other languages
English (en)
French (fr)
Inventor
Gregory P. CHANG
Ann F. CHEUNG
William Haney
Asya Grinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adimab LLC
Original Assignee
Adimab LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES18751476T priority Critical patent/ES3005783T3/es
Priority to KR1020257018720A priority patent/KR20250089564A/ko
Priority to CN201880023211.3A priority patent/CN110944651A/zh
Priority to CA3053010A priority patent/CA3053010A1/en
Priority to RU2019128060A priority patent/RU2809125C2/ru
Priority to RS20250083A priority patent/RS66445B1/sr
Priority to FIEP18751476.5T priority patent/FI3579848T3/fi
Priority to BR112019016315-8A priority patent/BR112019016315B1/pt
Priority to SG11201907299XA priority patent/SG11201907299XA/en
Priority to AU2018219887A priority patent/AU2018219887B2/en
Priority to KR1020247004661A priority patent/KR20240023449A/ko
Priority to EP24202255.6A priority patent/EP4491234A3/en
Priority to US16/483,330 priority patent/US11834506B2/en
Priority to JP2019563733A priority patent/JP2020506971A/ja
Priority to MX2019009468A priority patent/MX2019009468A/es
Priority to DK18751476.5T priority patent/DK3579848T3/da
Priority to EP18751476.5A priority patent/EP3579848B1/en
Priority to IL268554A priority patent/IL268554B2/en
Priority to KR1020197026247A priority patent/KR20190118172A/ko
Application filed by Adimab LLC filed Critical Adimab LLC
Publication of WO2018148445A1 publication Critical patent/WO2018148445A1/en
Anticipated expiration legal-status Critical
Priority to JP2022077006A priority patent/JP2022101709A/ja
Priority to US18/482,629 priority patent/US20240166753A1/en
Priority to JP2024077012A priority patent/JP2024099850A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

  • FIG. 6 is a representation of a TriNKET in the Orthogonal Fab interface (Ortho- Fab) form, which is an heterodimeric construct that contains 2 Fabs binding to target 1 and target 2 fused to Fc. LC-HC pairing is ensured by orthogonal interface. Heterodimerization is ensured by mutations in the F c .
  • FIG. 31 is a graph showing multi-specific binding proteins induced higher levels of cytotoxicity towards tumor target cells by human NK cells.
  • FIG. 35 is a graph showing multi-specific binding proteins induced higher levels of cytotoxicity towards tumor target cells by mouse NK cells.
  • tumor associated antigen means any antigen including but not limited to a protein, glycoprotein, ganglioside, carbohydrate, lipid that is associated with cancer. Such antigen can be expressed on malignant cells or in the tumor
  • salts include anions of the compounds of the present invention compounded with a suitable cation such as Na + , NH 4 + , and NW 4 + (wherein W
  • An alternative format of the heterodimeric multi- specific proteins includes a first immunoglobulin heavy chain, a second immunoglobulin heavy chain, a first immunoglobulin light chain and a second immunoglobulin light chain.
  • the first immunoglobulin heavy chain includes a first Fc (hinge-CH2-CH3) domain, a first variable heavy chain domain and an optional first CHI heavy chain domain.
  • the first immunoglobulin light chain includes a variable light chain domain and a constant light chain domain. Together with the first immunoglobulin heavy chain, the first immunoglobulin light chain forms an antigen-binding site that binds a tumor antigen.
  • T366S/L368A/Y407VCH3B The "hole" mutation was optimized by structured-guided phage library screening (Atwell S, Ridgway JB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol (1997) 270(l):26-35). X-ray crystal structures of KiH Fc variants (Elliott JM, Ultsch M, Lee J, Tong R, Takeda K, Spiess C, et al. , Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2-CH3 hydrophobic interaction.
  • TriNKETs described herein which include an NKG2D- binding domain and a binding domain for a tumor associated antigen, bind to cells expressing human NKG2D.
  • TriNKETs which include an NKG2D-binding domain and a binding domain for a tumor associated antigen, bind to the tumor associated antigen at a comparable level to that of a monoclonal antibody having the same tumor associated antigen-binding domain.
  • TriNKETs that include an NKG2D-binding domain and a HER2 -binding domain from Trastuzumab can bind to HER2 expressed on cells at a level comparable to that of Trastuzumab.
  • TriNKETs described herein e.g. , A40-TriNKET, A44-TriNKET, A49-TriNKET, C26-TriNKET, F04-TriNKET, F43-TriNKET, F47-TriNKET, and F63-TriNKET
  • a tumor associated antigen non-limiting examples of tumor associated antigens including
  • TriNKETs described herein including an NKG2D-binding domain e.g. , A40-TriNKET, A44-TriNKET, A49-TriNKET, C26-TriNKET, F04-TriNKET, F43 -TriNKET, F47-TriNKET, and F63 -TriNKET
  • a tumor associated antigen non-limiting examples of tumor associated antigens including CD20, BCMA, and HER2
  • TriNKETs including an NKG2D-binding domain and a tumor antigen-binding domain are more effective against cancer metastases than monoclonal antibodies that include the same tumor antigen-binding domain.
  • the amount of multi-specific binding protein and additional therapeutic agent and the relative timing of administration may be selected in order to achieve a desired combined therapeutic effect.
  • the therapeutic agents in the combination, or a pharmaceutical composition or compositions comprising the therapeutic agents may be administered in any order such as, for example, sequentially, concurrently, together, simultaneously and the like.
  • a multi-specific binding protein may be administered during a time when the additional therapeutic agent(s) exerts its prophylactic or therapeutic effect, or vice versa.
  • compositions that contain a therapeutically effective amount of a protein described herein (e.g. , A40-TriNKET, A44-
  • the formulation includes a buffer system which contains citrate and phosphate to maintain the pH in a range of about 4 to about 8.
  • the pH range may be from about 4.5 to about 6.0, or from about pH 4.8 to about 5.5, or in a pH range of about 5.0 to about 5.2.
  • the buffer system includes citric acid monohydrate, sodium citrate, disodium phosphate dihydrate, and/or sodium dihydrogen phosphate dihydrate.
  • the buffer system includes about 1.3 mg/ml of citric acid (e.g. , 1.305 mg/ml), about 0.3 mg/ml of sodium citrate (e.g.
  • the pH of the liquid formulation may be set by addition of a pharmaceutically acceptable acid and/or base.
  • the pH of the liquid formulation may be set by addition of a pharmaceutically acceptable acid and/or base.
  • pharmaceutically acceptable acid may be hydrochloric acid.
  • the base may be sodium hydroxide.
  • the lyoprotectant may be sugar, e.g. , disaccharides.
  • the lycoprotectant may be sucrose or maltose.
  • the lyophilized formulation may also include one or more of a buffering agent, a surfactant, a bulking agent, and/or a preservative.
  • the amount of sucrose or maltose useful for stabilization of the lyophilized drug product may be in a weight ratio of at least 1:2 protein to sucrose or maltose.
  • the protein to sucrose or maltose weight ratio may be of from 1 :2 to 1:5.
  • a “bulking agent” may be added.
  • a “bulking agent” is a compound which adds mass to a lyophilized mixture and contributes to the physical structure of the lyophilized cake (e.g. , facilitates the production of an essentially uniform lyophilized cake which maintains an open pore structure).
  • Illustrative bulking agents include mannitol, glycine, polyethylene glycol and sorbitol. The lyophilized formulations of the present invention may contain such bulking agents.
  • SC2.2 is single chain protein including an scFv derived from trastuzumab, and ULBP-6 (SEQ ID NO:73).
  • AL0.2 showed enhanced lysis of SkBr-3 target cells by human NK cells than trastuzumab in a does dependent manner, with a p value of 0.0311 in EC50 (FIG. 31).
  • the CD20-binding domain used in the tested molecules was composed of a heavy chain variable domain and a light chain variable domain.
  • the BCMA-binding domain used in the tested molecules was composed of a heavy chain variable domain and light chain variable domain as listed below.
  • Example 12 Trispecific-binding proteins enable cytotoxicity of target cancer cells
  • lOx lysis buffer was added to wells containing only cancer cells, and to wells containing only media for the maximum lysis and negative reagent controls, respectively. The plate was then placed back into the incubator for an additional 45 minutes to reach a total of 4 hours incubation. Cells were then pelleted, and the culture supernatant was transferred to a new 96 well plate and mixed with a substrate for development.
  • TriNKETs mediate cytotoxicity of human NK cells against the CD33-positive Molm-13 human AML cell line.
  • rested human NK cells were mixed with Molm- 13 cancer cells, and TriNKETs (e.g. , C26-TriNKET-CD33 and F04-TriNKET- CD33) are able to enhance the cytotoxic activity of rested human NK cells in a dose- responsive manner against the cancer cells.
  • the dotted line indicates cytotoxic activity of rested NK cells without TriNKETs.
  • NK cells The ability of human NK cells to lyse tumor cells was measured with or without the addition of TriNKETs using the cyto Tox 96 non-radioactive cytotoxicity assay from Promega (G1780).
  • Human cancer cell lines expressing a cancer target of interest were harvested from culture, cells were washed with PBS, and were resuspended in growth media at l-2xl0 5 /mL for use as target cells. 50 ⁇ of the target cell suspension were added to each well.
  • Monoclonal antibodies or TriNKETs targeting a cancer antigen of interest were diluted in culture media, 50 ⁇ of diluted mAb or TriNKET were added to each well.
  • NK cells were added to each well of the plate to make a total of 200 ⁇ culture volume. The plate was incubated at 37 °C with 5% C02 for 2-3 hours before developing the assay.
  • NK cells are activated by TriNKETs in co-culture with human cancer lines expressing varying levels of HER2
  • Trastuzumab + bispecific combination demonstrates the importance of containing the trispecific-binding of TriNKETs in one molecule.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
PCT/US2018/017470 2017-02-08 2018-02-08 Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer Ceased WO2018148445A1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
US16/483,330 US11834506B2 (en) 2017-02-08 2018-02-08 Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
CN201880023211.3A CN110944651A (zh) 2017-02-08 2018-02-08 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
CA3053010A CA3053010A1 (en) 2017-02-08 2018-02-08 Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
RU2019128060A RU2809125C2 (ru) 2017-02-08 2018-02-08 Полиспецифические связывающие белки для активации клеток-натуральных киллеров и их терапевтическое применение для лечения злокачественного новообразования
RS20250083A RS66445B1 (sr) 2017-02-08 2018-02-08 Multispecifični vezujući proteini za aktivaciju prirodnih ćelija ubica i njihova terapijska upotreba za lečenje raka
FIEP18751476.5T FI3579848T3 (fi) 2017-02-08 2018-02-08 Monispesifisiä sitovia proteiineja luonnollisten tappajasolujen aktivointiin ja niiden terapeuttisia käyttöjä syövän hoitoon
BR112019016315-8A BR112019016315B1 (pt) 2017-02-08 2018-02-08 Proteínas de ligação multiespecíficas para ativação de células natural killer e formulação que as compreende
SG11201907299XA SG11201907299XA (en) 2017-02-08 2018-02-08 Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
AU2018219887A AU2018219887B2 (en) 2017-02-08 2018-02-08 Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
KR1020247004661A KR20240023449A (ko) 2017-02-08 2018-02-08 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
EP24202255.6A EP4491234A3 (en) 2017-02-08 2018-02-08 Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
ES18751476T ES3005783T3 (en) 2017-02-08 2018-02-08 Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
JP2019563733A JP2020506971A (ja) 2017-02-08 2018-02-08 ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用
KR1020197026247A KR20190118172A (ko) 2017-02-08 2018-02-08 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
DK18751476.5T DK3579848T3 (da) 2017-02-08 2018-02-08 Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft
EP18751476.5A EP3579848B1 (en) 2017-02-08 2018-02-08 Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
IL268554A IL268554B2 (en) 2017-02-08 2018-02-08 Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
MX2019009468A MX2019009468A (es) 2017-02-08 2018-02-08 Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
KR1020257018720A KR20250089564A (ko) 2017-02-08 2018-02-08 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
JP2022077006A JP2022101709A (ja) 2017-02-08 2022-05-09 ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用
US18/482,629 US20240166753A1 (en) 2017-02-08 2023-10-06 Multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
JP2024077012A JP2024099850A (ja) 2017-02-08 2024-05-10 ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762456535P 2017-02-08 2017-02-08
US62/456,535 2017-02-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/483,330 A-371-Of-International US11834506B2 (en) 2017-02-08 2018-02-08 Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
US18/482,629 Continuation US20240166753A1 (en) 2017-02-08 2023-10-06 Multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer

Publications (1)

Publication Number Publication Date
WO2018148445A1 true WO2018148445A1 (en) 2018-08-16

Family

ID=63107062

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/017470 Ceased WO2018148445A1 (en) 2017-02-08 2018-02-08 Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer

Country Status (16)

Country Link
US (2) US11834506B2 (https=)
EP (2) EP4491234A3 (https=)
JP (3) JP2020506971A (https=)
KR (3) KR20240023449A (https=)
CN (1) CN110944651A (https=)
AU (1) AU2018219887B2 (https=)
CA (2) CA3053010A1 (https=)
DK (1) DK3579848T3 (https=)
ES (1) ES3005783T3 (https=)
FI (1) FI3579848T3 (https=)
IL (1) IL268554B2 (https=)
MX (1) MX2019009468A (https=)
PT (1) PT3579848T (https=)
RS (1) RS66445B1 (https=)
SG (1) SG11201907299XA (https=)
WO (1) WO2018148445A1 (https=)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3579876A4 (en) * 2017-02-10 2020-11-18 Dragonfly Therapeutics, Inc. PROTEINS BINDING BCMA, NKG2D AND CD16
EP3582806A4 (en) * 2017-02-20 2020-12-16 Dragonfly Therapeutics, Inc. HER2, NKG2D AND CD16 BOUND PROTEINS
WO2021009146A1 (en) 2019-07-15 2021-01-21 F. Hoffmann-La Roche Ag Antibodies binding to nkg2d
EP3630181A4 (en) * 2017-05-23 2021-03-17 Dragonfly Therapeutics, Inc. NKG2D BINDING PROTEIN, CD16 AND TUMOR ASSOCIATED ANTIGEN
EP3583131A4 (en) * 2017-02-20 2021-03-17 Dragonfly Therapeutics, Inc. PROTEINS THAT BIND CD33, NKG2D AND CD16
EP3583133A4 (en) * 2017-02-20 2021-04-14 Dragonfly Therapeutics, Inc. GD2, NKG2D AND CD16 BINDING PROTEINS
EP3630169A4 (en) * 2017-05-23 2021-04-21 Dragonfly Therapeutics, Inc. PROTEIN BINDING NKG2D, CD16 AND TUMOR ASSOCIATED ANTIGEN
EP3749347A4 (en) * 2018-02-08 2021-11-03 Dragonfly Therapeutics, Inc. COMBINATION THERAPY OF CANCER WITH MULTISPECIFIC BINDING PROTEINS THAT ACTIVATE NATURAL KILLER CELLS
WO2022031965A1 (en) 2020-08-05 2022-02-10 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and egfr
JP2022520978A (ja) * 2019-02-18 2022-04-04 クーリエ セラピューティクス インコーポレイテッド オルソポックスウイルス主要組織適合性複合体（ｍｈｃ）クラスｉ様タンパク質（ｏｍｃｐ）と腫瘍特異的結合パートナーを用いた二重特異性融合タンパク質
EP3802581A4 (en) * 2018-05-28 2022-04-13 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS AND IMPROVEMENTS THERETO
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
WO2023107956A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
US11834506B2 (en) 2017-02-08 2023-12-05 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
WO2024035662A2 (en) 2022-08-10 2024-02-15 Merck Sharp & Dohme Llc Proteins binding nkg2d, cd16, and ceacam5
WO2024056861A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for stimulating nk cells and use thereof
EP4173640A4 (en) * 2020-06-30 2024-08-14 GAIA BioMedicine Inc. METHOD FOR STABILIZING THE BINDING OF AN ANTIBODY ON AN NK CELL AND ASSOCIATED USE
US12103954B2 (en) 2021-10-20 2024-10-01 Synthekine, Inc. Heterodimeric Fc cytokines and uses thereof
US12157771B2 (en) 2020-05-06 2024-12-03 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
US12215157B2 (en) 2018-02-20 2025-02-04 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
US12275791B2 (en) 2018-08-08 2025-04-15 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use
EP4314080A4 (en) * 2021-03-31 2025-06-04 Janssen Biotech, Inc. MATERIALS AND METHODS FOR REDIRECTING IMMUNE EFFECTOR CELLS
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
US12377144B2 (en) 2021-03-03 2025-08-05 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
US12384851B2 (en) 2018-08-08 2025-08-12 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
WO2025191137A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of trop2-specific antigen binding proteins and cytokines
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120173123A (zh) * 2017-02-27 2025-06-20 蜻蜓疗法股份有限公司 靶向caix、ano1、间皮素、trop2、cea或紧密连接蛋白-18.2的多特异性结合蛋白
SG10202102502VA (en) * 2017-09-07 2021-04-29 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and a tumor-associated antigen
WO2019222449A1 (en) * 2018-05-16 2019-11-21 Dragonfly Therapeutics, Inc. Protein binding nkg2d, cd16 and a fibroblast activation protein
MX2021001510A (es) * 2018-08-08 2021-07-02 Dragonfly Therapeutics Inc Proteínas de union a nkg2d, cd16, y un antígeno asociado a tumores.
MX2022014208A (es) * 2020-05-21 2022-12-07 Merus Nv Metodos y medios para la produccion de moleculas tipo ig.
AU2021299573A1 (en) * 2020-07-03 2023-02-23 The Trustees Of Columbia University In The City Of New York Polyfunctional orthogonal protein chimeras
JP2023541694A (ja) * 2020-09-22 2023-10-03 ワールド バイオテック リジェネラティブ メディカル グループ リミテッド がん治療剤としての二重特異的抗原結合分子を有するｃａｒ発現ナチュラルキラー細胞の生成方法及び組成物
CN116948029A (zh) * 2022-04-20 2023-10-27 南京融捷康生物科技有限公司 一种包含IgG类Fc区变体的抗体及其用途
CN115058393B (zh) * 2022-07-13 2024-05-24 北京鼎成肽源生物技术有限公司 一种包被刺激物、培养试剂盒和自然杀伤细胞的培养方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879985B2 (en) 2007-12-14 2011-02-01 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
US20110044980A1 (en) 2009-07-29 2011-02-24 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
US9273136B2 (en) 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
US20160122432A1 (en) * 2013-06-11 2016-05-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
WO2016134371A2 (en) 2015-02-20 2016-08-25 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
WO2017081190A1 (en) * 2015-11-13 2017-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof

Family Cites Families (269)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366707A1 (en) 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoclonal antibodies to renal cell carcinoma
WO1989006544A1 (en) 1988-01-15 1989-07-27 Centocor, Inc. Heteroligating antibodies and therapeutic uses thereof
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6036955A (en) 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AU5509296A (en) 1995-05-03 1996-11-21 Colin Henry Self Bispecific antibodies in which the binding capability is rev ersibly inhibited by a photocleavable moiety
DE19531346A1 (de) 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
CZ302070B6 (cs) 1998-04-21 2010-09-29 Micromet Ag Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
ES2293748T3 (es) 1998-10-21 2008-03-16 Altor Bioscience Corporation Moleculas de fijacion poliespecificas y usos de las mismas.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CN1423700A (zh) 2000-03-24 2003-06-11 麦克美特股份公司 含有针对nkg2d受体复合物的表位的结合位点的多功能多肽
EP1299419A2 (en) 2000-05-24 2003-04-09 Imclone Systems, Inc. Bispecific immunoglobulin-like antigen binding proteins and method of production
US20040115198A1 (en) 2001-02-28 2004-06-17 Fred Hutchinson Cancer Research Center Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
US20020193569A1 (en) 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
DE10156482A1 (de) 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
CA2496419A1 (en) 2002-08-19 2004-02-26 Abgenix, Inc. Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
DE10261223A1 (de) 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
AU2004210088A1 (en) 2003-02-06 2004-08-19 Micromet Ag Trimeric polypeptide construct to induce an enduring T cell response
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
SI1629011T1 (sl) 2003-05-31 2010-05-31 Micromet Ag Humane molekule za vezavo anti hu cd
CA2522586C (en) 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US7803376B2 (en) 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
DE602004030811D1 (de) 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US20110020273A1 (en) 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
DK1716178T3 (da) 2004-02-16 2010-09-20 Micromet Ag Mindre immunogene bindingsmolekyler
AU2005263555B2 (en) 2004-07-16 2011-01-27 Amgen Research (Munich) Gmbh Expression-enhanced polypeptides
KR20140032004A (ko) 2004-07-22 2014-03-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
AU2005291039A1 (en) 2004-10-01 2006-04-13 Avidex Ltd. T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
EP3479844B1 (en) 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
EP1909832A4 (en) 2005-06-29 2010-01-13 Univ Miami ANTIBODY IMMUNOCELL LIGAND FUSION PROTEIN FOR CANCER THERAPY
EP1928495A2 (en) 2005-08-19 2008-06-11 Cerus Corporation Antibody-mediated enhancement of immune response
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
AU2006301492B2 (en) 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
AU2006301163B2 (en) 2005-10-14 2012-02-23 Innate Pharma Compositions and methods for treating proliferative disorders
WO2007048849A1 (en) 2005-10-28 2007-05-03 Novo Nordisk A/S Fusion proteins that bind effector lymphocytes and target cells
EP1945674A2 (en) 2005-11-03 2008-07-23 Genentech, Inc. Therapeutic anti-her2 antibody fusion polypeptides
EP1949107A1 (en) 2005-11-03 2008-07-30 Fred Hutchinson Cancer Research Center Negative immunomodulation of immune responses by nkg2d-positive cd4-positive cells
DK1976886T3 (en) 2005-12-16 2015-03-02 Amgen Res Munich Gmbh Means and methods for the treatment of tumor diseases
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
JP5161882B2 (ja) 2006-09-07 2013-03-13 クルセル ホランド ベー ヴェー インフルエンザウイルスｈ５ｎ１を中和しうるヒト結合性分子およびその使用
EP1900752A1 (en) 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
EP2183028A2 (en) 2007-07-25 2010-05-12 AstraZeneca AB Targeted binging agents directed to kdr and uses thereof - 035
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
MX2010008025A (es) 2008-01-22 2010-08-04 Biogen Idec Inc Anticuerpos ron y usos de los mismos.
BRPI0913366A8 (pt) 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
US8067339B2 (en) 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
EP2352758A2 (en) 2008-09-26 2011-08-10 Wyeth LLC Single chain antibody library design
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
WO2010080124A2 (en) 2008-12-18 2010-07-15 Dana-Farber Cancer Institute, Inc. Nkg2d-fc for immunotherapy
EP2376109B1 (en) 2008-12-19 2019-01-23 MacroGenics, Inc. Covalent diabodies and uses thereof
MX2011010166A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
WO2010132697A2 (en) 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treatment
US20130209514A1 (en) 2009-06-09 2013-08-15 Eli Gilboa Aptamer-targeted costimulatory ligand aptamer
SG177560A1 (en) 2009-07-06 2012-03-29 Hoffmann La Roche Bi-specific digoxigenin binding antibodies
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US9062287B2 (en) 2009-09-11 2015-06-23 Takara Bio Inc. Process for production of natural killer cells
CN107227335A (zh) 2009-10-27 2017-10-03 安进研发（慕尼黑）股份有限公司 用于施用CD19xCD3双特异性抗体的给药方案
WO2011057124A1 (en) 2009-11-06 2011-05-12 Transtarget, Inc. Polyclonal bispecific antibody compositions and method of use
EP2332994A1 (en) 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
WO2011075636A2 (en) 2009-12-18 2011-06-23 Amgen Inc. Wise binding agents and epitopes
US8658765B2 (en) 2009-12-31 2014-02-25 Avidbiotics Corp. Non-natural MIC proteins
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
DK3323830T3 (da) 2010-06-19 2023-09-25 Memorial Sloan Kettering Cancer Center Anti-gd2 antibodies
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
DE102010039018B4 (de) 2010-08-06 2013-02-28 Technische Universität Dresden Anti-La Antikörper und ihre Anwendung zum Immunotargeting
CA2808154A1 (en) 2010-08-13 2012-02-16 Medimmmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
JP5866130B2 (ja) 2010-09-10 2016-02-17 アペクシジェン， インコーポレイテッド 抗ＩＬ−１β抗体およびその使用方法
US20120263722A1 (en) 2010-11-04 2012-10-18 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
CA2817015A1 (en) 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
EP2686345B1 (en) 2011-03-16 2018-04-25 Amgen Inc. Fc variants
US9683052B2 (en) 2011-03-25 2017-06-20 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
CA2836873C (en) 2011-05-21 2019-10-22 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
US20140234342A1 (en) 2011-06-21 2014-08-21 Innate Pharma Nkp46-mediated nk cell tuning
DE102011118022B4 (de) 2011-06-30 2018-01-18 Gemoab Monoclonals Gmbh Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
CN109517059B (zh) * 2011-06-30 2023-03-28 中外制药株式会社 异源二聚化多肽
JP5938473B2 (ja) 2011-07-22 2016-06-22 アフィメート テラポイティクス アーゲー 多価抗原結合Ｆｖ分子
WO2013036799A2 (en) 2011-09-09 2013-03-14 Fred Hutchinson Cancer Research Center Methods and compositions involving nkg2d inhibitors and cancer
RU2732151C2 (ru) 2011-09-30 2020-09-11 Чугаи Сейяку Кабусики Кайся Библиотека зависимых от концентрации ионов связывающих молекул
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
LT2794658T (lt) 2011-12-19 2017-05-10 Synimmune Gmbh Bispecifinė antikūno molekulė
CA2861031C (en) 2012-02-03 2022-10-25 Carole BOURQUIN Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
TWI606064B (zh) 2012-02-08 2017-11-21 Ｉｇｍ生物科技公司 細胞死亡誘導分子（ｃｄｉｍ）結合蛋白類及彼等之用途
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US9029510B2 (en) 2012-03-30 2015-05-12 Sorrento Therapeutics, Inc. Fully human antibodies that bind to VEGFR2 and methods of use thereof
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
US9163090B2 (en) 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
EP3795215A1 (en) 2012-05-30 2021-03-24 Chugai Seiyaku Kabushiki Kaisha Target tissue-specific antigen-binding molecule
EP4310191A3 (en) 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
WO2013192594A2 (en) 2012-06-21 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind c-met
MX354862B (es) 2012-06-27 2018-03-23 Hoffmann La Roche Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
WO2014012085A2 (en) 2012-07-13 2014-01-16 Zymeworks Inc. Bispecific asymmetric heterodimers comprising anti-cd3 constructs
US20140072581A1 (en) 2012-07-23 2014-03-13 Zymeworks Inc. Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
EP3470431A1 (en) 2012-09-27 2019-04-17 Merus N.V. Bispecific igg antibodies as t cell engagers
CN104271602B (zh) 2012-11-21 2020-08-21 武汉友芝友生物制药有限公司 双特异性抗体
EP3878964A1 (en) 2012-11-27 2021-09-15 Ajou University Industry-Academic Cooperation Foundation Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
KR20200024345A (ko) 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
CA2898100C (en) 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
US10047163B2 (en) 2013-02-08 2018-08-14 Abbvie Stemcentrx Llc Multispecific constructs
MX375359B (es) 2013-02-26 2025-03-06 Roche Glycart Ag Moléculas biespecíficas de unión a antígeno activadoras de células t.
JP6676521B2 (ja) 2013-03-14 2020-04-08 マクロジェニクス，インコーポレーテッド 二重特異性分子、薬学的組成物及びそれらの使用
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
CA2902739C (en) 2013-03-15 2022-11-22 Xencor, Inc. Heterodimeric proteins
CN105705165B (zh) 2013-03-15 2020-04-24 纪念斯隆-凯特琳癌症中心 高亲和力抗gd2抗体
WO2014165818A2 (en) 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
US20140323315A1 (en) 2013-04-29 2014-10-30 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
EP3415534A1 (en) 2013-05-10 2018-12-19 Numab Therapeutics AG Bispecific constructs and their use in the treatment of various diseases
US9908944B2 (en) 2013-07-15 2018-03-06 Novo Nordisk A/S Antibodies that bind urokinase plasminogen activator
CA2916681A1 (en) 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
CN105722859B (zh) 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
GB2518221A (en) 2013-09-16 2015-03-18 Sergej Michailovic Kiprijanov Tetravalent antigen-binding protein molecule
EP3046938B1 (en) 2013-09-16 2019-12-04 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Bi- or multispecific polypeptides binding immune effector cell surface antigens and hbv antigens for treating hbv infections and associated conditions
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
JP6553069B2 (ja) 2013-11-07 2019-07-31 メモリアル スローン ケタリング キャンサー センター 抗ｗｔ１／ｈｌａ二重特異性抗体
DE102013019352A1 (de) 2013-11-13 2015-09-17 Elke Pogge Von Strandmann Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort
EA201691214A1 (ru) 2013-12-13 2016-12-30 Дженентек, Инк. Антитела к cd33 и иммуноконъюгаты
EP3327038B1 (en) 2013-12-20 2020-09-23 F. Hoffmann-La Roche AG Bispecific her2 antibodies and methods of use
EP3083682B1 (en) 2013-12-20 2024-04-17 F. Hoffmann-La Roche AG Dual specific antibodies
SG11201605093VA (en) 2013-12-23 2016-07-28 Zymeworks Inc Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof
BR112016015140A2 (pt) 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
US20160326249A1 (en) 2014-01-15 2016-11-10 Zymeworks Inc. Bi-specific cd3 and cd19 antigen-binding constructs
CN112094347A (zh) 2014-03-05 2020-12-18 奥托路斯有限公司 具有针对T细胞受体beta恒定区的抗原结合域的嵌合抗原受体(CAR)
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
EP3126384B1 (en) 2014-04-01 2020-12-02 Adimab, LLC Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
MX2016012830A (es) 2014-04-11 2017-01-05 Medimmune Llc Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
EP2930188A1 (en) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
EP2942629A1 (en) 2014-05-08 2015-11-11 Universität Würzburg Predictive markers for successful cancer immunotherapy
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
WO2015197582A1 (en) 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
JP6822849B2 (ja) 2014-06-27 2021-01-27 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的ＮＫｐ４６結合タンパク質
CA2952532A1 (en) 2014-06-27 2015-12-30 Innate Pharma Multispecific antigen binding proteins
BR112016030740A2 (pt) 2014-07-01 2018-02-20 Pfizer Inc. diacorpos heterodiméricos biespecíficos e seus usos
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
US9777073B2 (en) 2014-07-21 2017-10-03 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody EpCAM×CD3
WO2016011571A1 (en) 2014-07-21 2016-01-28 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody-mediated cancer therapy with cytokine-induced killer cell
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
JP2017533255A (ja) 2014-08-28 2017-11-09 アカデミス・ジーケンハイス・ライデン・ハー・オー・デー・エヌ・エルユーエムセーＡｃａｄｅｍｉｓｃｈ Ｚｉｅｋｅｎｈｕｉｓ Ｌｅｉｄｅｎ Ｈ．Ｏ．Ｄ．Ｎ． Ｌｕｍｃ Ｃｄ９４／ｎｋｇ２ａおよび／またはｃｄ９４／ｎｋｇ２ｂ抗体、ワクチンの組み合わせ
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
EP3215531A1 (en) 2014-11-03 2017-09-13 Merck Patent GmbH Methods for generating bispecific shark variable antibody domains and use thereof
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
EP4043474A1 (en) * 2014-12-05 2022-08-17 Xyphos Biosciences Inc. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
CA2970255A1 (en) 2014-12-17 2016-06-23 Intrexon Corporation Intercalated single-chain variable fragments
US10941207B2 (en) 2014-12-19 2021-03-09 Chiome Bioscience, Inc Fusion protein comprising three binding domains to 5T4 and CD3
JP6744313B2 (ja) 2015-01-02 2020-08-26 ダイアックス コーポレーション 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
WO2016115274A1 (en) 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
AR100680A1 (es) * 2015-01-26 2016-10-26 Macrogenics Inc Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos
MA41613A (fr) 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US11673957B2 (en) 2015-03-10 2023-06-13 Eureka Therapeutics, Inc. Anti-ROR2 antibodies
JP6726676B2 (ja) 2015-03-16 2020-07-22 ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ Ｍｕｅｎｃｈｅｎ Ｄｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） Ｈｂｖ感染および関連症状を治療するための三重特異的結合分子
AU2016243026B2 (en) 2015-04-03 2022-03-31 Eureka Therapeutics, Inc. Constructs targeting AFP peptide/MHC complexes and uses thereof
RS61907B1 (sr) 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena
CN107708733B (zh) 2015-04-07 2022-11-15 艾利妥 抗分拣蛋白抗体和其使用方法
PL3988117T3 (pl) 2015-04-13 2025-03-10 Pfizer Inc. Przeciwciała terapeutyczne i ich zastosowania
WO2016166139A1 (en) 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
EP3842072A1 (en) 2015-05-18 2021-06-30 Eureka Therapeutics, Inc. Anti-ror1 antibodies
EP3095792A1 (en) 2015-05-19 2016-11-23 Klinikum rechts der Isar der Technischen Universität München T cell receptor with specificity for myeloperoxidase peptide and uses thereof
US20180147257A1 (en) 2015-05-22 2018-05-31 The Board Of Trustees Of The Leland Stanford Junior University Btn3a ectodomain proteins and methods of use
TN2019000101A1 (en) 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
CN107708741A (zh) 2015-06-12 2018-02-16 免疫医疗公司 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
JP7497953B2 (ja) 2015-06-12 2024-06-11 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
WO2016207278A1 (en) 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins
DK3313876T3 (da) 2015-06-23 2025-04-22 Innate Pharma Multispecifikke antigenbindende proteiner
CA2991264C (en) 2015-07-06 2023-10-10 Ucb Biopharma Sprl Tau-binding antibodies
WO2017011342A1 (en) 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
WO2017008169A1 (en) 2015-07-15 2017-01-19 Zymeworks Inc. Drug-conjugated bi-specific antigen-binding constructs
HK1255234A1 (zh) 2015-07-16 2019-08-09 塞勒兰特治疗公司 经半胱氨酸取代的免疫球蛋白
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
EP3349792A1 (en) 2015-09-14 2018-07-25 Compass Therapeutics LLC Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-
PE20240096A1 (es) 2015-10-02 2024-01-18 Hoffmann La Roche Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
CA3003458A1 (en) 2015-10-29 2017-05-04 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
EP4074731A1 (en) 2015-11-04 2022-10-19 City of Hope Chimeric antigen receptors targeting her2
US10815290B2 (en) 2015-11-10 2020-10-27 Fred Hutchinson Cancer Research Center NKG2D decoys
CN115925933A (zh) 2015-12-28 2023-04-07 依奈特制药公司 NKp46结合蛋白的可变区
MA43874A (fr) 2016-01-13 2018-11-21 Compass Therapeutics Llc Constructions de liaison à l'antigène immunomodulateur multispécifique
WO2017125897A1 (en) 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
TW201730212A (zh) 2016-02-17 2017-09-01 宏觀基因股份有限公司 Ｒｏｒ１－結合分子及其使用方法
EP3419667A4 (en) 2016-02-26 2019-10-23 Imunexus Pty Ltd MULTISPECIFIC MOLECULES
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
CN109153727A (zh) 2016-04-15 2019-01-04 酵活有限公司 靶向免疫治疗剂的多特异性抗原结合构建体
TWI781098B (zh) 2016-04-15 2022-10-21 美商宏觀基因股份有限公司 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
SI3468586T1 (sl) 2016-06-14 2025-01-31 Xencor, Inc. Bispecifična protitelesa za zaviralce kontrolnih točk
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN105906722B (zh) 2016-06-24 2020-02-07 安徽未名细胞治疗有限公司 一种Her2特异性嵌合抗原受体及其应用
EP3507307A4 (en) 2016-09-01 2020-04-22 Immunomab, Inc. BISPECIFIC ANTIBODIES
US20190225702A1 (en) 2016-10-14 2019-07-25 Harpoon Therapeutics, Inc. Innate immune cell trispecific binding proteins and methods of use
EP3532091A2 (en) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
WO2018148447A1 (en) 2017-02-08 2018-08-16 Adimab, Llc Antibody heavy chain variable domains targeting the nkg2d receptor
SG11201907299XA (en) 2017-02-08 2019-09-27 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
MA47465A (fr) 2017-02-10 2019-12-18 Dragonfly Therapeutics Inc Protéines fixant le bcma, le nkg2d et le cd16
CA3053275A1 (en) 2017-02-10 2018-08-16 Dragonfly Therapeutics, Inc. Proteins binding psma, nkg2d and cd16
IL268755B2 (en) * 2017-02-20 2025-12-01 Dragonfly Therapeutics Inc Proteins that bind her2, nkg2d, and cd16
CA3054078A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding cd33, nkg2d and cd16
CA3054086A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding cd123, nkg2d and cd16
BR112019017256A2 (pt) 2017-02-20 2020-04-14 Dragonfly Therapeutics Inc proteínas de ligação gd2, nkg2d e cd16
CN120173123A (zh) 2017-02-27 2025-06-20 蜻蜓疗法股份有限公司 靶向caix、ano1、间皮素、trop2、cea或紧密连接蛋白-18.2的多特异性结合蛋白
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
AU2018273250A1 (en) 2017-05-23 2019-12-12 Dragonfly Therapeutics, Inc. A protein binding NKG2D, CD16 and a tumor-associated antigen
KR20200010430A (ko) 2017-05-23 2020-01-30 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질
MX2019013998A (es) 2017-05-23 2020-07-29 Dragonfly Therapeutics Inc Una proteína que se une al receptor nkg2d, al antígeno de cúmulo de diferenciación 16 (cd16) y receptores huérfanos tipo tirosina quinasa 1 o 2 (ror1 o ror2).
BR112020001972A2 (pt) 2017-07-31 2020-08-04 Dragonfly Therapeutics, Inc. proteínas de ligação a nkg2d, cd16 e flt3
AU2018318698A1 (en) 2017-08-16 2020-02-20 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16, and EGFR, HLA-E CCR4, or PD-L1
AU2018322178A1 (en) 2017-08-23 2020-02-20 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
SG10202102502VA (en) 2017-09-07 2021-04-29 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and a tumor-associated antigen
SG11202002298PA (en) 2017-09-14 2020-04-29 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1)
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
EA202091887A1 (ru) 2018-02-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
EP3755348A4 (en) 2018-02-20 2022-03-02 Dragonfly Therapeutics, Inc. Antibody variable domains targeting cd33, and use thereof
EP3773676A4 (en) 2018-04-03 2022-05-18 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
US20220025037A1 (en) 2018-04-03 2022-01-27 Dragonfly Therapeutics, Inc. Antibody variable domains targeting dll3, and use thereof
EP3790585A4 (en) 2018-05-07 2022-05-11 Dragonfly Therapeutics, Inc. PROTEIN-BINDING NKG2D, CD16 AND TUMOR-ASSOCIATED ANTIGEN
WO2019222449A1 (en) 2018-05-16 2019-11-21 Dragonfly Therapeutics, Inc. Protein binding nkg2d, cd16 and a fibroblast activation protein
EA202091977A1 (ru) 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
MX2021001510A (es) 2018-08-08 2021-07-02 Dragonfly Therapeutics Inc Proteínas de union a nkg2d, cd16, y un antígeno asociado a tumores.
AU2019366956B2 (en) 2018-10-23 2025-10-30 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins
AU2020226493B2 (en) 2019-02-18 2025-10-23 Recourse Biologics, Inc. Bispecific fusion protein using orthopoxvirus major histocompatibility complex (MHC) class l-like protein (OMCP) and tumor-specific binding partner
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
AU2020337999A1 (en) 2019-08-30 2022-03-24 Dragonfly Therapeutics, Inc. Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind HER2, NKG2D, and CD16 for cancer treatment
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879985B2 (en) 2007-12-14 2011-02-01 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
US9273136B2 (en) 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
US20110044980A1 (en) 2009-07-29 2011-02-24 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US20160122432A1 (en) * 2013-06-11 2016-05-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
WO2016134371A2 (en) 2015-02-20 2016-08-25 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
WO2017081190A1 (en) * 2015-11-13 2017-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY
ATWELL SRIDGWAY JBWELLS JACARTER P.: "Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library", J MOL BIOL, vol. 270, no. 1, 1997, pages 1975 - 35, XP002610109, DOI: 10.1006/jmbi.1997.1116
AVERDAM, A ET AL.: "A Novel System of Polymorphic and Diverse NK Cell Receptors in Primates", PLOS GENETICS, vol. 5, no. 10, October 2009 (2009-10-01), pages 1 - 15, XP055537277 *
DOPPALAPUDI VR ET AL., PNAS, vol. 107, no. 52, 2010, pages 22611 - 22616
ELLIOTT JMULTSCH MLEE JTONG RTAKEDA KSPIESS C ET AL.: "Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2-CH3 hydrophobic interaction", J MOL BIOL, vol. 426, no. 9, 2014, pages 1947 - 57, XP028844614, DOI: 10.1016/j.jmb.2014.02.015
LABRIJN ET AL., NATURE PROTOCOLS, vol. 9, pages 2450 - 2463
LANGER, SCIENCE, vol. 249, 1990, pages 1527 - 1533
LEWIS SMWU XPUSTILNIK ASERENO AHUANG FRICK HL ET AL.: "Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface", NAT. BIOTECHNOL., vol. 32, no. 2, 2014, pages 191 - 8, XP055240003, DOI: 10.1038/nbt.2797
LIN, Z ET AL.: "CD4 + NKG2D + T cells induce NKG2D down-regulation in natural killer cells in CD86-RAE-1 ε transgenic mice", IMMUNOLOGY, vol. 141, no. 3, March 2014 (2014-03-01), pages 401 - 415, XP055537274 *
MIMOTO FKADONO SKATADA HIGAWA TKAMIKAWA THATTORI K.: "Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcgammaRs", MOL IMMUNOL, vol. 58, no. 1, 2014, pages 132 - 8, XP028548629, DOI: 10.1016/j.molimm.2013.11.017
MUDA M. ET AL., PROTEIN ENG. DES. SEL., vol. 24, no. 5, 2011, pages 447 - 54
NICOLE C. SMITS ET AL., EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 16, no. 9
See also references of EP3579848A4
SMITS, NC ET AL.: "Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer", EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 16, no. 9, September 2016 (2016-09-01), pages 1105 - 1112, XP055537271 *
SONDERMANN ET AL., NATURE, vol. 406, no. 6793, pages 267 - 273
STEIGERWALD J. ET AL., PLOS ONE, vol. 9, no. 10, 7 October 2014 (2014-10-07)
STEIMER ET AL., CLINICA CHIMICA ACTA, vol. 308, 2001, pages 33 - 41
SZUN SZUN TAY ET AL.: "TriKEs and BiKEs join CARs on the cancer immunotherapy highway", HUMAN VACCINES & IMMUNOTHERAPIES, vol. 12, no. 11, 20 June 2016 (2016-06-20)
WRANIK, BJ. ET AL., J. BIOL. CHEM., vol. 287, 2012, pages 43331 - 9

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11834506B2 (en) 2017-02-08 2023-12-05 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
EP3579876A4 (en) * 2017-02-10 2020-11-18 Dragonfly Therapeutics, Inc. PROTEINS BINDING BCMA, NKG2D AND CD16
EP3583133A4 (en) * 2017-02-20 2021-04-14 Dragonfly Therapeutics, Inc. GD2, NKG2D AND CD16 BINDING PROTEINS
AU2018220736B2 (en) * 2017-02-20 2024-10-24 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
EP3583131A4 (en) * 2017-02-20 2021-03-17 Dragonfly Therapeutics, Inc. PROTEINS THAT BIND CD33, NKG2D AND CD16
EP4273258A3 (en) * 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
EP3582806A4 (en) * 2017-02-20 2020-12-16 Dragonfly Therapeutics, Inc. HER2, NKG2D AND CD16 BOUND PROTEINS
US11884732B2 (en) 2017-02-20 2024-01-30 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
AU2018220734B2 (en) * 2017-02-20 2025-03-06 Dragonfly Therapeutics, Inc. Proteins binding CD33, NKG2D and CD16
EP3630169A4 (en) * 2017-05-23 2021-04-21 Dragonfly Therapeutics, Inc. PROTEIN BINDING NKG2D, CD16 AND TUMOR ASSOCIATED ANTIGEN
EP3630181A4 (en) * 2017-05-23 2021-03-17 Dragonfly Therapeutics, Inc. NKG2D BINDING PROTEIN, CD16 AND TUMOR ASSOCIATED ANTIGEN
US12384847B2 (en) 2018-02-08 2025-08-12 Dragonfly Therapeutics, Inc. Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
US12129300B2 (en) 2018-02-08 2024-10-29 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
EP3749347A4 (en) * 2018-02-08 2021-11-03 Dragonfly Therapeutics, Inc. COMBINATION THERAPY OF CANCER WITH MULTISPECIFIC BINDING PROTEINS THAT ACTIVATE NATURAL KILLER CELLS
US12264200B2 (en) 2018-02-08 2025-04-01 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US11939384B1 (en) 2018-02-08 2024-03-26 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US12215157B2 (en) 2018-02-20 2025-02-04 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
EP3802581A4 (en) * 2018-05-28 2022-04-13 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS AND IMPROVEMENTS THERETO
US12384851B2 (en) 2018-08-08 2025-08-12 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
US12275791B2 (en) 2018-08-08 2025-04-15 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use
JP2022520978A (ja) * 2019-02-18 2022-04-04 クーリエ セラピューティクス インコーポレイテッド オルソポックスウイルス主要組織適合性複合体（ｍｈｃ）クラスｉ様タンパク質（ｏｍｃｐ）と腫瘍特異的結合パートナーを用いた二重特異性融合タンパク質
US11827711B2 (en) 2019-07-15 2023-11-28 Hoffmann-La Roche Inc. Antibodies binding to NKG2D
JP2022541163A (ja) * 2019-07-15 2022-09-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｎｋｇ２ｄに結合する抗体
JP7586889B2 (ja) 2019-07-15 2024-11-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｎｋｇ２ｄに結合する抗体
WO2021009146A1 (en) 2019-07-15 2021-01-21 F. Hoffmann-La Roche Ag Antibodies binding to nkg2d
US12157771B2 (en) 2020-05-06 2024-12-03 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
EP4173640A4 (en) * 2020-06-30 2024-08-14 GAIA BioMedicine Inc. METHOD FOR STABILIZING THE BINDING OF AN ANTIBODY ON AN NK CELL AND ASSOCIATED USE
EP4585611A2 (en) 2020-08-05 2025-07-16 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and egfr
WO2022031965A1 (en) 2020-08-05 2022-02-10 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and egfr
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
US12377144B2 (en) 2021-03-03 2025-08-05 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
EP4314080A4 (en) * 2021-03-31 2025-06-04 Janssen Biotech, Inc. MATERIALS AND METHODS FOR REDIRECTING IMMUNE EFFECTOR CELLS
US12522639B2 (en) 2021-10-20 2026-01-13 Synthekine, Inc. Heterodimeric FC cytokines and uses thereof
US12103954B2 (en) 2021-10-20 2024-10-01 Synthekine, Inc. Heterodimeric Fc cytokines and uses thereof
WO2023107956A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2024035662A2 (en) 2022-08-10 2024-02-15 Merck Sharp & Dohme Llc Proteins binding nkg2d, cd16, and ceacam5
WO2024056861A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for stimulating nk cells and use thereof
WO2024056862A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
WO2025191137A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of trop2-specific antigen binding proteins and cytokines
WO2025191144A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of egfr-specific antigen binding proteins and cytokines
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191139A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of her2-specific antigen binding proteins and cytokines

Also Published As

Publication number Publication date
IL268554A (en) 2019-09-26
US20190359716A1 (en) 2019-11-28
EP3579848B1 (en) 2024-10-30
JP2024099850A (ja) 2024-07-25
DK3579848T3 (da) 2025-01-20
KR20190118172A (ko) 2019-10-17
RU2019128060A (ru) 2021-03-09
EP3579848A1 (en) 2019-12-18
RS66445B1 (sr) 2025-02-28
CA3221995A1 (en) 2018-08-16
EP4491234A2 (en) 2025-01-15
KR20250089564A (ko) 2025-06-18
CN110944651A (zh) 2020-03-31
US20240166753A1 (en) 2024-05-23
JP2020506971A (ja) 2020-03-05
CA3221995C (en) 2024-05-28
RU2019128060A3 (https=) 2021-06-10
EP3579848A4 (en) 2021-03-03
JP2022101709A (ja) 2022-07-06
US11834506B2 (en) 2023-12-05
KR20240023449A (ko) 2024-02-21
FI3579848T3 (fi) 2025-01-22
PT3579848T (pt) 2025-01-30
AU2018219887A1 (en) 2019-08-22
IL268554B1 (en) 2024-11-01
CA3053010A1 (en) 2018-08-16
MX2019009468A (es) 2020-01-20
EP4491234A3 (en) 2025-04-09
AU2018219887B2 (en) 2024-08-15
IL268554B2 (en) 2025-03-01
ES3005783T3 (en) 2025-03-17
SG11201907299XA (en) 2019-09-27
BR112019016315A2 (pt) 2020-03-31

Similar Documents

Publication Publication Date Title
US20240166753A1 (en) Multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
US20240228625A1 (en) Proteins binding her2, nkg2d and cd16
US20230303702A1 (en) Combination therapy of cancer involving multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigen
US20200095327A1 (en) Antibody heavy chain variable domains targeting the nkg2d receptor
US20240018266A1 (en) Proteins binding cd123, nkg2d and cd16
EP3583131A1 (en) Proteins binding cd33, nkg2d and cd16
EP3579876A1 (en) Proteins binding bcma, nkg2d and cd16
US20200231700A1 (en) Proteins binding gd2, nkg2d and cd16
US20200024353A1 (en) Proteins binding psma, nkg2d and cd16
HK40019176B (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
HK40019176A (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18751476

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3053010

Country of ref document: CA

Ref document number: 2019563733

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019016315

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2018219887

Country of ref document: AU

Date of ref document: 20180208

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20197026247

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018751476

Country of ref document: EP

Effective date: 20190909

ENP Entry into the national phase

Ref document number: 112019016315

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190807

WWR Wipo information: refused in national office

Ref document number: 519402413

Country of ref document: SA

WWE Wipo information: entry into national phase

Ref document number: P-2025/0083

Country of ref document: RS

WWG Wipo information: grant in national office

Ref document number: P-2025/0083

Country of ref document: RS

WWD Wipo information: divisional of initial pct application

Ref document number: 1020257018720

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1020257018720

Country of ref document: KR